Spectral ai reaches 50% enrollment at burn centers for u.s. pivotal burn study

Dallas, june 06, 2024 (globe newswire) -- spectral ai, inc. (nasdaq: mdai) (“spectral ai” or the “company”), an artificial intelligence (ai) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 50% clinical trial site enrollment at burn centers for its 2024 pivotal study designed to validate the algorithm used by its deepview™ system for burn indication. this pivotal study, which is targeting enrollment of 240 patients, including both adult and pediatric subjects at multiple burn centers and emergency departments across the u.s., is expected to be the final clinical trial before seeking fda approval in 2025.
MDAI Ratings Summary
MDAI Quant Ranking